The story of Sildenafil offers a intricate case study for investors eyeing drug companies. While early sales were explosive, recent patent expiration and the emergence of generic versions have severely influenced https://nikolasekeg442076.blue-blogs.com/49197178/the-blue-pill-and-pharma-a-dangerous-stake